<![CDATA[Anselamimab’s Kappa Subgroup Signal Could Reshape Anti-Fibril Therapy in AL Amyloidosis]]>

Data ReadoutpositiveanselamimabPositive

AI Analysis

Summary

Anselamimab showed a positive signal in kappa light chain amyloidosis subgroup, potentially reshaping the role of anti-fibril therapy in AL amyloidosis treatment. The benefit profile is being explored by Dr. Meletios A. Dimopoulos in clinical discussions.

Clinical Trial Data

Outcome Details

Anselamimab demonstrated benefit in kappa light chain amyloidosis subgroup

Importance:5/10

Sentiment:

0.60

AL amyloidosiskappa light chainanti-fibril therapyclinical data

Read the original article

Published by Cancer Network on September 24, 2026 12:00 PM

Read Original